Animal cells and systems

The Korean Society for Integrative Biology (한국통합생물학회)
권호 표지

Changes in the Hypothalamic Gonadotropin-Releasing Hormone Gene Expression and the Pituitary Luteinizing Hormone Immunoreactivity in Male Rats: Comparison of Clozapine with Typical Antipsychotics

  • Kim, Myeong-Ok (Department of Biology, College of Natural Sciences) ;
  • Koh, Phil-Ok (Department of Biology, College of Natural Sciences) ;
  • Kim, Jin-Hyun (Department of Anatomy, College of Medicine, Gyeongsang National University) ;
  • Chung, Ki-Myung (Department of Anatomy, College of Medicine, Gyeongsang National University) ;
  • Kang, Sang-Soo (Department of Anatomy, College of Medicine, Gyeongsang National University) ;
  • Park, Wan-Sung (Department of Anatomy, College of Medicine, Gyeongsang National University)
  • Published : 2000.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Evidence suggested that atypical antipsychotics (APs) such as clozapine show less side effects than those of typical APs such as haloperidol and sulpiride. However, little is known about chronic effects of these drugs on changes in gonadotropin releasing hormone (GnRH) mRNA expression and luteinizing hormone (LH) immunoreactivity. Male rats were divided into water-, haloperidol-, sulpiride-, and clozapine-treated groups, and these drugs were administered orally for 4 weeks. The changes in the expression of GnRH mRNA and the LH immunoreactivity were determined in the hypothalamus and pituitary, respectively, using in situ hybridization and immunohistochemistry. GnRH mRNAs were clearly expressed in the water-treated control vats. This was significantly reduced by the chronic treatments with the typical APs, especially with haloperidol, but not with atypical APs clozapine. Likewise, LH immunoreactivity was clearly stained in the control group. While its immunoreativity was significantly reduced by the chronic APs treatments, clozapine treatment showed only slight attenuation. The results show that the atypical APs clozapine has less side effects in the gonadal function than the typical APs haloperidol and the sulpiride. These results suggest that clozapine is a safer drug than the typical APs, at least in the reproductive system.

Keywords

References

  1. Angerer, LM, Cox KH, and Angerer RC (1987) Demonstration of tissue-specific gene expression by in situ hybridization. Methods Enzymol 152: 649-661 https://doi.org/10.1016/0076-6879(87)52071-7
  2. Bjorklund A and Nobin A (1973) Fluorescence histochemical and microspectrofluormetric mapping of dopamine and noradrenaline cell grops in the rat diencephalon. Brain Res 51: 193-205 https://doi.org/10.1016/0006-8993(73)90372-7
  3. Brann DW and Malesh VB (1991) Regulation of gonadotropin secretion by steroid hormones. Frontier Neuroendocrinol 12: 165-207
  4. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179-203 https://doi.org/10.1016/0893-133X(88)90012-7
  5. Farde l, Wiesel FA, Halldin G, and Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiat 45: 71-76
  6. Fade L, Nordstrom AL, and Wiesel FA (1992) Position emission tomographic in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiat 49: 538-544
  7. Fuxe K, Hokfelt T, Lofstrom A, Johansson O, Agnati L, Everelt B, Goldstein M, Jeffcoate S, White N, Eneroth P, Gustafsson J, and Skett P (1976) On the role of neurotransmitters and hypothalamic hormones and their interactions in hypothalamic and extrahypothalamic control of pituitary function and sexual behavior. In: Naftolin F, Ryan KJ, and Davies T(eds), Subcellular Mechanisms in Reproductive Neuroendocrinology, Elsevier, Amsterdam, pp 193-246
  8. Gallo RV (1980) Neuroendocrine regulation of pulsatile luteinizing hormone release in the rat. Neuroedocrinology 30: 122-131
  9. Hodson CA, Simpkins JW, Pass KA, Aylsworth CF, Steger RW, and Meites J (1980) Effects of a prolactin-secretion pituitary tumor on hypothalamic, gonadotropic and testicular function in male rats. Neuroendocrinology 30: 7-10
  10. Jennes L, Stumpf WE, and Tappaz ML (1983) Anatomical relationships of dopaminergic and GABAergic systems with the GnRH systems in the septohypothalamic area-immunohistochemical studies. Exp Brain Res 50: 91-99
  11. Kalra PS and Kalra SP (1985) Control of gonoaotropin sesretion. In: Imura H (ed), The Piturtary Gland, Raven Press, New York, pp 189-219
  12. Kapur S and Remington G (1996) Serotonin-dopamine interaction and its elevance to schizophrenia. Am J Psychiat 153: 466-476
  13. Keck PE Jr and McElroy SL (1997) The new anitipsychotics and their therapeutic potential. Psychiat Ann 27: 320-331
  14. Li L and Pelletier G (1992a) Role of dopamine in the regulation of gonadotropin-releasing hormone in the male rat brain as studies by in situ hybridization. Endocrinology 131: 395-399 https://doi.org/10.1210/en.131.1.395
  15. Li S and Pelletier G (1992b) Dopamine regulation of gonadotropin-releasing hormone (GnRH) gene expression in the female rat brain. Neurosci Lett 146: 207-210 https://doi.org/10.1016/0304-3940(92)90079-M
  16. Melmed S (1995) The Pituitary. Blackwell science, Cambridge 149-162
  17. Meltzer HY, Goode DJ, AND Schyve PM (1979) Effevt of clozapine on human serum prolactin levels. Am J Psychiat 136: 1550-1555
  18. Mycek MJ, harvey RA, and Champe PC (2000) Lipponcott's llnstrated Reviews: Pharmacology, 2nd Ed. Lippincott & Williams & Watkins, New YOrk, pp 127-132
  19. Negrop-Vilar A, Ojeda SR, and McCann SM (1979) Catecholamineergic modulation of luteinizing hormone-releasing hormone release by median eminence terminals in vitro. Endorcrinology 104: 1749-1757
  20. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, and Sedvall G (1995) D1-D2 and 5-HT2 receptor occupancy in relation to clozapine serum concentration- a PET study of schizophrenic patients. Am J Psychiat 152: 1444-1449
  21. Owens RE, Fleeger JL, Harms PG (1980) Evidence for central nervous system (CNS) involvement in inhibition of luteinizing hormone (LH) release by dopamine receptor stimulation. Endocrinol Res Commun 7: 99-105
  22. Park SK and Selmanoff M (1991) Dose-dependent suppression of postcastration luteinizing hormone secretion exerted by exogenous prolactin administrantion in male rats: A model for studying hyperprolactinemic hypogonadism. Neuroedocrinology 53: 404-410
  23. Rubin RT (1987) Prolactin and schizophrenia. In; Melzer HY(ed), Psychopharmacology: The Thied Generation of Progress, Raven Press, New York, pp 803-808
  24. Schneider HP and McCann SM (1969) Possible role of dopamine as transmitter to promote discharge of LH-releasing factor. Endocrinology 85: 121-132
  25. Tasaka K, Miyake A, Sakumoto T, and Aono T (1985) Dopamine decreases release of luteinizing hormone from superfused rat mediobasal hypothalamus. J Endocrinol Invest 8: 373-376
  26. Tortonese DJ and Lincoln GA (1994) Photoperiodic modulation of the dopaminergic contral of pulsatile LH secretion in sheep. J Endocrinol 143: 25-32
  27. Vance ML (1997) New dierctions in the treatment of hyperprolactinemia. Endocrinologist 7: 153-159
  28. Vijayan E and McCann SM (1978) Re-evaluation of the role of catecholamines in control of gonadotropin and prolatin release. Neuroendocrinology 25: 150-165
  29. Yamada T, Nakamura J, Murakami M, Okuno Y, Hospkawa S, Matsuo M, and Yamada H (1995) Effect of chronic L-DOPA administration on serum luteinzing hormone levels in male rats. Toxicology 97 : 173-182 https://doi.org/10.1016/0300-483X(94)02946-R
  30. Yazigi RA, Quintero CH, and Salameh WA (1997) Prolactin discorders. Fertil steril 67: 215-225 https://doi.org/10.1016/S0015-0282(97)81900-0